Skip to main content
Premium Trial:

Request an Annual Quote

DeCode s Shares Recede Slightly from Gains On Positive Drug Data

Click here for an updated version of this article.

NEW YORK, Oct. 19 (GenomeWeb News) - Shares in DeCode Genetics this afternoon slipped to $6.97 from their high of $7.70, reached this morning after the company announced positive results from an ongoing drug trial.

 

Shares in the Icelandic pharmacogenomics company closed at $6.61 on the Nasdaq yesterday.

 

As GenomeWeb News reported, DeCode licensed the drug, which is in early-stage Phase IIa testing, from Bayer last November


Results of the study showed the drug, called DG031, to have significantly reduced levels of two chemical biomarkers associated with arterial inflammation and myocardial infarction risk.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.